Advertisement

Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings

Published:November 23, 2007DOI:https://doi.org/10.1016/j.amjcard.2007.07.049
      When it is difficult to deliver multiple drug-eluting stents (DES) or when size constraints limit DES implantation, bare-metal stents (BMS) may be implanted contiguous to DES. However, the clinical outcomes after overlapping DES and BMS implantation are not known. From September 2004 to June 2006, 4,872 consecutive patients who underwent percutaneous coronary intervention consented to be enrolled in a prospective registry. Of these patients, 44 (0.9%) with de novo lesions were treated with DES and BMS overlap stenting. All patients were followed to 12 months for the assessment of clinical outcomes. The average implanted stent diameter was 2.68 ± 0.30 mm for DES and 2.35 ± 0.38 mm for BMS. Overlapping BMS were implanted distal to DES in all but 1 case. One patient (2.3%) experienced acute stent thrombosis and died 2 days after the procedure. No other patient died or had a myocardial infarction during 12 months. The target vessel revascularization rate at 12 months, however, was 31.8%, mainly driven by diffuse in-stent restenosis in the BMS segments. In conclusion, the incidence of DES and BMS overlap stenting is rare in daily practice, but this procedure is associated with a high rate of target vessel revascularization.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • Holmes D.R.
        • O’Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • et al.
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1523
        • Stone G.W.
        • Ellis S.G.
        • Cox D.A.
        • Hermiller J.
        • O’Shaughnessy C.
        • Mann J.T.
        • Turco M.
        • Caputo R.
        • Bergin P.
        • Greenberg J.
        • et al.
        A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
        N Engl J Med. 2004; 350: 221-231
        • Ellis S.G.
        • Vandormael M.G.
        • Cowley M.J.
        • DiSciascio G.
        • Deligonul U.
        • Topol E.J.
        • Bulle T.M.
        Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease.
        Circulation. 1990; 82: 1193-1202
        • Balakrishnan B.
        • Tzafriri A.R.
        • Seifert P.
        • Groothuis A.
        • Rogers C.
        • Edelman E.R.
        Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents.
        Circulation. 2005; 111: 2958-2965
        • Burzotta F.
        • Siviglia M.
        • Altamura L.
        • Trani C.
        • Leone A.M.
        • Romagnoli E.
        • Mazzari M.A.
        • Mongiardo R.
        • Niccoli G.
        • Brancati M.
        • et al.
        Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents.
        Am J Cardiol. 2007; 99: 364-368
        • Takano M.
        • Murakami D.
        • Mizuno K.
        Overlapping hybrid stenting with a sirolimus-eluting stent and a bare metal stent.
        Int J Cardiol. 2007; 118: e8-e10
        • Biondi-Zoccai G.G.
        • Agostoni P.
        • Sangiorgi G.M.
        • Airoldi F.
        • Cosgrave J.
        • Chieffo A.
        • Barbagallo R.
        • Tamburino C.
        • Vittori G.
        • Falchetti E.
        • et al.
        Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation.
        Eur Heart J. 2006; 27: 540-546
        • Stone G.W.
        • Ellis S.G.
        • Cannon L.
        • Mann J.T.
        • Greenberg J.D.
        • Spriggs D.
        • O’Shaughnessy C.D.
        • DeMaio S.
        • Hall P.
        • Popma J.J.
        • et al.
        Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
        JAMA. 2005; 294: 1215-1223
        • Moreno R.
        • Fernandez C.
        • Hernandez R.
        • Alfonso F.
        • Angiolillo D.J.
        • Sabate M.
        • Escaned J.
        • Banuelos C.
        • Fernandez-Ortiz A.
        • Macaya C.
        Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
        J Am Coll Cardiol. 2005; 45: 954-959
        • Lemos P.A.
        • Arampatzis C.A.
        • Saia F.
        • Hoye A.
        • Degertekin M.
        • Tanabe K.
        • Lee C.H.
        • Cummins P.
        • Smits P.C.
        • McFadden E.
        • et al.
        Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry).
        Am J Cardiol. 2004; 93: 633-636
        • Moses J.W.
        • Nikolsky E.
        • Mehran R.
        • Cambier P.A.
        • Bachinsky W.B.
        • Leya F.
        • Kuntz R.E.
        • Popma J.J.
        • Schleckser P.
        • Wang H.
        • et al.
        Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
        Am J Cardiol. 2006; 98: 1455-1460
        • Tsagalou E.
        • Chieffo A.
        • Iakovou I.
        • Ge L.
        • Sangiorgi G.M.
        • Corvaja N.
        • Airoldi F.
        • Montorfano M.
        • Michev I.
        • Colombo A.
        Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.
        J Am Coll Cardiol. 2005; 45: 1570-1573
        • Kereiakes D.J.
        • Wang H.
        • Popma J.J.
        • Kuntz R.E.
        • Donohoe D.J.
        • Schofer J.
        • Schampaert E.
        • Meier B.
        • Leon M.B.
        • Moses J.W.
        Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.
        J Am Coll Cardiol. 2006; 48: 21-31
        • Chu W.W.
        • Kuchulakanti P.K.
        • Torguson R.
        • Wang B.
        • Clavijo L.C.
        • Suddath W.O.
        • Pichard A.D.
        • Satler L.F.
        • Kent K.M.
        • Waksman R.
        Comparison of clinical outcomes of overlapping sirolimus- versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2006; 98: 1563-1566
        • Kandzari D.E.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • O’Shaughnessy C.
        • Ball M.W.
        • Turco M.
        • Applegate R.J.
        • Gurbel P.A.
        • Midei M.G.
        • et al.
        Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
        J Am Coll Cardiol. 2006; 48: 2440-2447
        • Serruys P.W.
        • Ruygrok P.
        • Neuzner J.
        • Piek J.J.
        • Seth A.
        • Schofer J.
        • Richardt G.
        • Wiemer M.
        • Carrie D.
        • Tuhuesen L.
        • et al.
        A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial.
        Eurointervention. 2006; 2: 286-294